BlackRock Fund Advisors’s Myriad Genetics MYGN Stock Holding History

BlackRock Fund Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$54.4M	Buy	3,264,023 +473,788	+17%	+$8.57M	0.01%	1626
2016 Q3	$57.4M	Buy	2,790,235 +127,246	+5%	+$3.23M	0.01%	1482
2016 Q2	$81.5M	Sell	2,662,989 -67,926	-2%	-$2.36M	0.02%	1139
2016 Q1	$102M	Buy	2,730,915 +72,034	+3%	+$2.71M	0.02%	938
2015 Q4	$115M	Sell	2,658,881 -128,091	-5%	-$5.41M	0.03%	853
2015 Q3	$104M	Buy	2,786,972 +59,360	+2%	+$2.11M	0.03%	871
2015 Q2	$92.7M	Buy	2,727,612 +1,111,593	+69%	+$37.8M	0.02%	1056
2015 Q1	$57.2M	Buy	1,616,019 +135,261	+9%	+$4.84M	0.01%	1423
2014 Q4	$50.4M	Sell	1,480,758 -10,017	-0.7%	-$355K	0.01%	1459
2014 Q3	$57.5M	Buy	1,490,775 +23,333	+2%	+$871K	0.02%	1270
2014 Q2	$57.1M	Sell	1,467,442 -26,886	-2%	-$1M	0.02%	1312
2014 Q1	$51.1M	Buy	1,494,328 +51,866	+4%	+$1.61M	0.02%	1403
2013 Q4	$30.3M	Sell	1,442,462 -15,171	-1%	-$384K	0.01%	1736
2013 Q3	$34.3M	Buy	1,457,633 +183,450	+14%	+$5.21M	0.01%	1604
2013 Q2	$34.2M	Buy	+1,274,183	New	+$36.9M	0.01%	1478

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

SCM

Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

BlackRock Fund Advisors's MYGN Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Myriad Genetics (MYGN) stake by 17% in Q4 2016, buying an estimated $8.57M and bringing the position to 3,264,023 shares worth $54.4M. The position accounts for 0.01% of the portfolio, ranked #1626.

BlackRock Fund Advisors first reported a position in MYGN in Q2 2013 and has held it in 15 quarters since. The position peaked at $115M in Q4 2015. 223 funds tracked by Wall St. Rank hold MYGN as of Q4 2016.

BlackRock Fund Advisors held 3,264,023 shares of Myriad Genetics worth $54.4M as of Q4 2016.
BlackRock Fund Advisors bought 473,788 Myriad Genetics shares in Q4 2016, an estimated $8.57M.
Myriad Genetics made up 0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1626 holding.
BlackRock Fund Advisors first reported a position in Myriad Genetics in Q2 2013 and has held it in 15 quarters since.
BlackRock Fund Advisors's Myriad Genetics position peaked at $115M in Q4 2015.
223 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.